ZKB/CALL/ELI LILLY & CO/900/0.01/27.09.24 | Real-time Bid/Ask 07:03:46 2024-06-06 am EDT | ||
| 0.33 CHF / 0.34 CHF | -1.47% |
|
| Current month | +13.33% | ||
| 1 month | +142.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-06-04 | 0.34 | -2.86% |
| 24-06-03 | 0.35 | +16.67% |
| 24-05-30 | 0.3 | +3.45% |
| 24-05-29 | 0.29 | +3.57% |
Delayed Quote Swiss Exchange
Last update June 04, 2024 at 11:20 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | ZKB |
| LLYAIZ | |
| ISIN | CH1305143419 |
| Date issued | 2024-03-08 |
| Strike | 900 $ |
| Maturity | 2024-09-27 (114 Days) |
| Parity | 100 : 1 |
| Emission price | 0.46 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.37 CHF |
|---|---|
| Lowest since issue | 0.14 CHF |
| Spread | 0.01 CHF |
| Spread % | 3.03% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
831.8
USD
Average target price
852.5
USD
Spread / Average Target
+2.50%
- Stock Market
- Warrants
- LLYAIZ Warrant
